X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20163) 20163
Book Review (3443) 3443
Publication (1832) 1832
Conference Proceeding (145) 145
Book Chapter (111) 111
Dissertation (45) 45
Magazine Article (29) 29
Web Resource (18) 18
Reference (6) 6
Book / eBook (5) 5
Government Document (5) 5
Paper (4) 4
Streaming Video (4) 4
Journal / eJournal (2) 2
Newspaper Article (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14657) 14657
humans (14198) 14198
imatinib mesylate (11778) 11778
imatinib (8594) 8594
oncology (6964) 6964
benzamides (6845) 6845
male (5940) 5940
female (5496) 5496
pyrimidines - therapeutic use (5125) 5125
piperazines - therapeutic use (4744) 4744
middle aged (4703) 4703
antineoplastic agents - therapeutic use (4674) 4674
hematology (4423) 4423
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (4230) 4230
adult (4110) 4110
chronic myelogenous leukemia (3769) 3769
chronic myeloid-leukemia (3658) 3658
aged (3553) 3553
chronic myeloid leukemia (3357) 3357
cancer (2952) 2952
treatment outcome (2631) 2631
animals (2623) 2623
pyrimidines - pharmacology (2618) 2618
protein kinase inhibitors - therapeutic use (2508) 2508
piperazines - pharmacology (2359) 2359
leukemia (2344) 2344
bcr-abl (2146) 2146
mutation (2091) 2091
therapy (2015) 2015
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1915) 1915
antineoplastic agents - pharmacology (1846) 1846
dasatinib (1838) 1838
protein-tyrosine kinases - antagonists & inhibitors (1790) 1790
prognosis (1658) 1658
tyrosine kinase inhibitor (1657) 1657
tyrosine kinase (1619) 1619
care and treatment (1596) 1596
gastrointestinal stromal tumors (1592) 1592
pyrimidines - administration & dosage (1550) 1550
mice (1539) 1539
fusion proteins, bcr-abl - genetics (1485) 1485
protein kinase inhibitors - pharmacology (1485) 1485
pharmacology & pharmacy (1471) 1471
hemic and lymphatic diseases (1464) 1464
tumors (1459) 1459
research (1451) 1451
tyrosine (1441) 1441
gastrointestinal stromal tumors - drug therapy (1437) 1437
aged, 80 and over (1427) 1427
leukemia, myelogenous, chronic, bcr-abl positive - pathology (1427) 1427
abridged index medicus (1426) 1426
cml (1423) 1423
piperazines - administration & dosage (1376) 1376
pyrimidines - adverse effects (1363) 1363
c-kit (1351) 1351
cell line, tumor (1344) 1344
resistance (1334) 1334
analysis (1322) 1322
drug resistance, neoplasm (1318) 1318
adolescent (1303) 1303
tyrosine kinase inhibitors (1294) 1294
medicine & public health (1262) 1262
antineoplastic agents (1249) 1249
apoptosis (1225) 1225
antineoplastic agents - adverse effects (1212) 1212
young adult (1206) 1206
gist (1202) 1202
chemotherapy (1183) 1183
expression (1166) 1166
nilotinib (1162) 1162
mesylate (1149) 1149
piperazines - adverse effects (1142) 1142
antimitotic agents (1114) 1114
antineoplastic agents - administration & dosage (1105) 1105
drug therapy (1096) 1096
gastrointestinal stromal tumors - pathology (1062) 1062
gastrointestinal stromal tumor (1055) 1055
diagnosis (1053) 1053
kinases (1030) 1030
proto-oncogene proteins c-kit - genetics (1027) 1027
surgery (1017) 1017
hematology, oncology and palliative medicine (1008) 1008
cell biology (998) 998
mutations (965) 965
survival (959) 959
kit (952) 952
genetic aspects (949) 949
retrospective studies (926) 926
apoptosis - drug effects (907) 907
health aspects (885) 885
neoplasms (869) 869
in-vitro (865) 865
philadelphia-chromosome (858) 858
article (854) 854
cells (845) 845
fusion proteins, bcr-abl - metabolism (826) 826
pathology (823) 823
biochemistry & molecular biology (799) 799
follow-up (793) 793
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (785) 785
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18456) 18456
Japanese (397) 397
French (349) 349
Chinese (308) 308
German (272) 272
Spanish (186) 186
Russian (77) 77
Polish (76) 76
Korean (72) 72
Czech (40) 40
Italian (36) 36
Portuguese (36) 36
Hungarian (33) 33
Turkish (26) 26
Danish (10) 10
Dutch (10) 10
Croatian (9) 9
Romanian (6) 6
Slovenian (6) 6
Swedish (5) 5
Slovak (4) 4
Ukrainian (4) 4
Finnish (3) 3
Hebrew (3) 3
Bulgarian (2) 2
Norwegian (2) 2
Persian (2) 2
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 660 - 662
Estimates suggest that nearly 30% of patients diagnosed with chronic myeloid leukemia (CML) are aged <49 years, with approximately half being women. For many... 
ONCOLOGY | IMATINIB
Journal Article
Leukemia, ISSN 0887-6924, 07/2018, Volume 32, Issue 7, pp. 1657 - 1669
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | RANDOMIZED CML | ONCOLOGY | COMPLETE MOLECULAR REMISSION | LONG-TERM SURVIVAL | MANAGING CHILDREN | RECEIVING IMATINIB | DOSE IMATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EUROPEAN-LEUKEMIANET | Prognosis | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Imatinib Mesylate - therapeutic use | Neoplasm Grading | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Treatment Failure | Imatinib Mesylate - administration & dosage | Female | Child | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Treatment Outcome | Combined Modality Therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Bone Marrow - pathology | Adolescent | Biomarkers | Neoplasm Staging | Adolescence | Imatinib | Myeloid leukemia | Complications | Leukemia | Stem cell transplantation | Transplantation | Chronic myeloid leukemia | Survival | Patients | Molecular chains | Intolerance | Side effects | Failure analysis | Stem cells | Children | Adolescents | Index Medicus
Journal Article
10/2011
Background: Treatment of cancers with cytotoxic agents such as tyrosine kinase inhibiting drugs often, but not always, result in transient to permanent... 
Imatinib | testosterone | lactate dehydrogenase
Web Resource
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 16, pp. 2423 - 2433
Journal Article
Journal Article
Urology, ISSN 0090-4295, 07/2019, Volume 129, pp. 206 - 209
Dermtofibrosarcoma protuberans is a rare cutaneous malignancy known to be locally aggressive. It is uncommonly seen in the pediatric population and can be... 
UROLOGY & NEPHROLOGY | IMATINIB
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 01/2014, Volume 24, Issue 1, pp. 52 - 61
OBJECTIVEThe tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia are substrates for the efflux transport protein ATP-binding... 
CGP74588 | Imatinib | Pharmacogenetics | Tyrosine kinase inhibitor | Single-nucleotide polymorphism | Chronic myeloid leukemia | N-desmethyl imatinib | ABCG2 | LOCALIZATION | STEM-CELLS | PROTEIN | STANDARD-DOSE IMATINIB | imatinib | TRANSPORTER ABCG2 | P-GLYCOPROTEIN | RESPONSES | PHARMACOKINETICS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | RESISTANCE | chronic myeloid leukemia | PHARMACOLOGY & PHARMACY | PATIENTS RECEIVING IMATINIB | tyrosine kinase inhibitor | single-nucleotide polymorphism | pharmacogenetics | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Nitriles - pharmacology | Benzamides - pharmacokinetics | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Neoplasm Proteins - metabolism | Nitriles - pharmacokinetics | Quinolines - pharmacology | Thiazoles - pharmacokinetics | Genetic Variation | Quinolines - pharmacokinetics | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette Transporters - metabolism | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Membrane - metabolism | Piperazines - pharmacokinetics | Neoplasm Proteins - genetics | Protein Kinase Inhibitors - pharmacokinetics | Cell Line | Dasatinib | Aniline Compounds - pharmacology | Transduction, Genetic | Genotype | Aniline Compounds - pharmacokinetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | K562 Cells | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Mutation | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN | ABCG2; CGP74588; chronic myeloid leukemia; imatinib; N-desmethyl imatinib; pharmacogenetics; single-nucleotide polymorphism; tyrosine kinase inhibitor
Journal Article
01/2010
Imatinib is a clinically well-tolerated small molecule inhibitor that exerts selective, dual inhibition on the transforming growth factor beta and... 
Angle | imatinib | conformation
Web Resource
08/2012
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative expansion of primitive hematopoietic progenitor cells. Materials and Methods: In the... 
myeloid leukemia | Imatinib | philadelphia chromosome
Web Resource
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1
The correct table can be viewed here: thumbnail Download: * PPT PowerPoint slide * PNG larger image * TIFF original image Figures Citation: Schiavon G,... 
Imatinib
Journal Article